Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics


Inhibikase Therapeutics Inc. (IKT): $0.94

0.04 (+4.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IKT Stock Price Chart Interactive Chart >

Price chart for IKT

IKT Price/Volume Stats

Current price $0.94 52-week high $6.41
Prev. close $0.89 52-week low $0.60
Day low $0.90 Volume 102,600
Day high $0.98 Avg. volume 121,521
50-day MA $1.11 Dividend yield N/A
200-day MA $1.57 Market Cap 23.61M

Inhibikase Therapeutics Inc. (IKT) Company Bio


Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.


IKT Latest News Stream


Event/Time News Detail
Loading, please wait...

IKT Latest Social Stream


Loading social stream, please wait...

View Full IKT Social Stream

Latest IKT News From Around the Web

Below are the latest news stories about Inhibikase Therapeutics Inc that investors may wish to consider to help them evaluate IKT as an investment opportunity.

Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Ab...

Benzinga | January 17, 2022

Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today highlighted recent developments and anticipated milestones for 2022.

Yahoo | January 5, 2022

Reviewing Genocea Biosciences (NASDAQ:GNCA) and Inhibikase Therapeutics (NYSE:IKT)

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics []

Dakota Financial News | December 20, 2021

Contrasting Inhibikase Therapeutics (IKT) & Its Competitors

Inhibikase Therapeutics (NYSE: IKT) is one of 237 publicly-traded companies in the Biological products, except diagnostic industry, but how does it compare to its rivals? We will compare Inhibikase Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership. Valuation & Earnings This table compares []

Dakota Financial News | December 5, 2021

Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out

In last trading session, Inhibikase Therapeutics Inc. (NASDAQ:IKT) saw 0.55 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $1.65 trading at -$0.12 or -6.78% at ring of the bell on the day assigns it a market valuation of $41.25M. That closing price of IKTs stock is Inhibikase Therapeutics Inc. (NASDAQ:IKT) Has Recovered -2.42% So Far, But Another -627.27% Loss Cannot Be Ruled Out Read More »

Marketing Sentinel | December 4, 2021

Read More 'IKT' Stories Here

IKT Price Returns

1-mo -6.47%
3-mo -12.96%
6-mo -55.87%
1-year -82.43%
3-year N/A
5-year N/A
YTD -36.05%
2021 -78.70%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6263 seconds.